Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Lymphoma, T-Cell, Peripheral 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

Cisplatin 86Radiotherapy 71Paclitaxel 50Fluorouracil 38Carboplatin 36Drug Therapy 32Neoadjuvant Therapy 23toripalimab 19tislelizumab 18pembrolizumab 17camrelizumab 17Irinotecan 17Esophagectomy 17Surgical Procedures, Operative 16Radiation 16Docetaxel 16sintilimab 15Oxaliplatin 14130-nm albumin-bound paclitaxel 14nimotuzumab 11TP protocol 11S 1 (combination) 11Radiotherapy, Intensity-Modulated 11Cetuximab 11Capecitabine 11Albumin-Bound Paclitaxel 10apatinib 9Leucovorin 9Immune Checkpoint Inhibitors 8nedaplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Squamous Cell Carcinoma × ivarmacitinib × Clear all
NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡